Research programme: tuberculosis therapies - Global Alliance for TB Drug Development

Drug Profile

Research programme: tuberculosis therapies - Global Alliance for TB Drug Development

Alternative Names: NITD 304; PA-824 analogues; Pretomanid analogues

Latest Information Update: 22 Aug 2014

Price : $50

At a glance

  • Originator Global Alliance for TB Drug Development; Novartis Institute for Tropical Diseases
  • Developer Global Alliance for TB Drug Development
  • Class Amides; Indoles; Nitroimidazoles; Small molecules
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 20 Aug 2014 Novartis Institute for Tropical Diseases grants Global Alliance for TB Drug Development an exclusive global license for all further development and distribution of the tuberculosis therapies programme
  • 27 Jun 2012 Preclinical development is ongoing USA and Singapore
  • 16 Jul 2010 Preclinical development is ongoing in USA and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top